Janus Henderson Group PLC Has $35.06 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Janus Henderson Group PLC decreased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 35.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,897,340 shares of the biotechnology company’s stock after selling 1,021,738 shares during the quarter. Janus Henderson Group PLC owned approximately 2.08% of Rocket Pharmaceuticals worth $35,055,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of RCKT. Erste Asset Management GmbH acquired a new position in shares of Rocket Pharmaceuticals during the third quarter valued at $825,000. Maverick Capital Ltd. raised its holdings in Rocket Pharmaceuticals by 4.8% during the 3rd quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company’s stock worth $76,072,000 after purchasing an additional 190,360 shares during the last quarter. Verition Fund Management LLC acquired a new position in Rocket Pharmaceuticals during the 3rd quarter valued at about $290,000. Rockefeller Capital Management L.P. boosted its stake in shares of Rocket Pharmaceuticals by 24.1% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 107,912 shares of the biotechnology company’s stock valued at $1,993,000 after purchasing an additional 20,939 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Rocket Pharmaceuticals during the 3rd quarter worth approximately $2,556,000. 98.39% of the stock is currently owned by institutional investors.

Insider Activity at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 11,091 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $13.05, for a total value of $144,737.55. Following the transaction, the chief executive officer now owns 707,328 shares of the company’s stock, valued at approximately $9,230,630.40. The trade was a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 13,490 shares of company stock worth $176,045. 28.50% of the stock is owned by company insiders.

Rocket Pharmaceuticals Stock Up 4.3 %

Shares of Rocket Pharmaceuticals stock opened at $13.89 on Friday. The company has a market capitalization of $1.27 billion, a P/E ratio of -5.05 and a beta of 1.01. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The business has a 50-day moving average of $16.02 and a two-hundred day moving average of $19.24. Rocket Pharmaceuticals, Inc. has a 1 year low of $12.62 and a 1 year high of $32.53.

Analysts Set New Price Targets

Several brokerages recently weighed in on RCKT. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Chardan Capital restated a “buy” rating and issued a $62.00 price target on shares of Rocket Pharmaceuticals in a research report on Monday, November 18th. Leerink Partners dropped their price objective on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday, November 19th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.